NEWS

March 6, 2019

Infinity Pharmaceuticals Announces Royalty Monetization of COPIKTRA™ for $30 Million Gross Proceeds

March 1, 2019

Portola Pharmaceuticals Enters into $125 Million Loan Agreement with HealthCare Royalty Partners and Athyrium Capital Management

February 27, 2019

Paratek Pharmaceuticals Reports Fourth Quarter and Full Year 2018 Financial Results

January 7, 2019

Coherus BioSciences Secures $75 Million Credit Financing with HealthCare Royalty Partners

November 5, 2018

Grünenthal Acquires Global Rights for Qutenza^®

November 2, 2018

U.S. FDA Approves UDENYCA™ (pegfilgrastim-cbqv)

October 23, 2018

Gary A. Lyons Joins HealthCare Royalty Partners Senior Advisor Board

September 25, 2018

Coherus Biosciences Receives European Commission Approval for UDENYCA™ (Pegfilgrastim Biosimilar)

May 24, 2018

Portola Pharmaceuticals Receives $100 Million Milestone Payment from HealthCare Royalty Partners for FDA Approval of Andexxa®

May 14, 2018

U.S. Food and Drug Administration Accepts and Acknowledges Coherus Biosciences Biologics License Application of CHS-1701 (Pegfilgrastim Biosimilar Candidate) For Review